Kisqali has received FDA approval for adjuvant early breast cancer, with a target decision date of September 2024 [1]. This approval is for the CDK4/6 inhibitor in combination with endocrine therapy for adults with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence [2].
What are the key clinical trial results supporting Kisqali's approval?
The FDA's decision is based on data from the Phase III NATALEE trial. In this trial, Kisqali in combination with endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to endocrine therapy alone [3]. The study enrolled over 5,000 participants and met its primary endpoint, showing a reduction in the risk of breast cancer recurrence or death [3].
When does Kisqali's patent exclusivity end?
DrugPatentWatch.com tracks patent expirations for medications. While specific patent expiry dates can be complex and subject to change, information regarding Kisqali's patent landscape can be found on their platform [4]. Exclusivity periods can be influenced by various factors, including patent challenges and regulatory extensions.
What is the mechanism of action for Kisqali?
Kisqali is a selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. These kinases are crucial for cell cycle progression. By inhibiting CDK4 and CDK6, Kisqali aims to halt the proliferation of cancer cells by blocking the cell cycle at the G1 to S phase transition [2].
How does Kisqali compare to other CDK4/6 inhibitors for early breast cancer?
While Kisqali is now approved for adjuvant early breast cancer, other CDK4/6 inhibitors like Verzenio (abemaciclib) have also received approvals in this setting [5]. Verzenio, also used in combination with endocrine therapy, has shown similar benefits in reducing the risk of recurrence in certain patient populations with high-risk early breast cancer [5]. The choice between these agents may depend on specific patient characteristics, trial data, and physician recommendations.
What are the potential risks and side effects associated with Kisqali?
Common side effects reported in clinical trials for Kisqali include neutropenia, diarrhea, nausea, vomiting, fatigue, and decreased appetite [2]. The NATALEE trial reported manageable toxicity, with strategies in place to mitigate side effects [3]. Patients are advised to discuss potential risks and side effects thoroughly with their healthcare providers.
What does "adjuvant" mean in the context of breast cancer treatment?
Adjuvant therapy is administered after primary treatment, such as surgery, to reduce the risk of cancer recurrence. In the case of early breast cancer, adjuvant treatment aims to eliminate any microscopic cancer cells that may have spread from the original tumor but are not detectable by imaging tests [2].
---
Sources:
[1] FDA
[2] Novartis
[3] The NATALEE trial
[4] DrugPatentWatch.com
[5] Lilly